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Arthur Van Zee: Dr. Jones’s paper is very informative.
I found much that was new to me even after 7 months’
experience with buprenorphine. I wish I had it when
we were starting out.
Martin Doot:The information in this article is con-
sistent with other reviews of buprenorphine therapy
I’ve seen. I wish it had more on the psychosocial aspects
of drug treatment, though. 
J. Thomas Payte: If I had only one source, this arti-
cle is the one I would want to have. When it is pub-
lished, I want all the physicians in our programs to
have it as background reading. I particularly liked the
explanations of how partial agonists work and how
they differ from full agonists and antagonists. 
Programs and strategies
Van Zee: We are looking to buprenorphine as a pos-
sible solution to a very difficult situation. Our clinic
is in the heart of Appalachia, in the southwestern cor-
ner of Virginia. Until about 3 years ago we had no
large-scale opioid addiction, but the OxyContin epi-
demic changed that. There are now tens of thousands
of new opioid addicts in our region. Methadone treat-
ment programs may be 2 hours away by car. Try to
imagine a 23-year-old single mother getting her daugh-
ter up at 4:30 every morning to drive to Tennessee
to get a methadone dose. Because of these difficulties,
prior to buprenorphine, I would just detox patients
and set them up with our local counseling team. Now,
I can offer them comprehensive treatment with an
effective medication.
We’ve had some wonderful success stories already—
people who started induction 7 months ago and who
have come very far, not just in terms of abstinence,
but also in terms of real personal growth. We’ve also
had many lapses. I think I’ve initiated 46 patients
on buprenorphine; 23 are still in the program, and
about 15 to 17 are doing well.
Doot: I work in a multispecialty, office-based group
practice affiliated with a large teaching hospital near
Chicago. We’re looking at buprenorphine as a means
to incorporate more flexibility into our abstinence-
based treatment model. We intend to offer it for 
maintenance as well as to improve outcomes with 
abstinence-based treatment.
Our group participated in the buprenorphine
clinical trials because our State agency wanted an 
abstinence-based perspective on the medication. Patients
chose buprenorphine or traditional abstinence-based
therapy. Our counselors found that after a while they
had a group of patients they were encouraging to
use 12-step facilitation and relapse prevention tech-
niques, who were well past detox but still using buprenor-
phine. What came out of this was a new model, in
which we meet patients where they are, accept some
of the goals they set for themselves, and then move
them along the continuum of change.
Our counselors are comfortable with this model.
I’ve had some say to me, ‘I really think this patient
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would do better on maintenance.’ That never hap-
pened before.
Payte: I have been in addiction medicine full-time
since the 1960s and was involved in one of the last
clinical trials of buprenorphine. Now I work for Colonial
Management Group, which operates 43 methadone
treatment programs in 14 States. The physicians in
our organization have shown intense interest in buprenor-
phine, and we are now gearing up to use it. For me,
buprenorphine is particularly promising because of
its safety and flexibility. It’s not as strong as methadone,
and has long-lasting action, so you don’t see signifi-
cant problems if a patient misses one or two doses,
as you do with methadone.
Which patients?
Doot: The new medication will be particularly useful
for patients who cannot achieve recovery through tra-
ditional abstinence-based programs. Some people drop
out of these programs because the biological dimen-
sion of their addiction is so powerful they can’t get
past it to begin to address the other tasks of treat-
ment—healing their family, healing the way they think,
entering a spiritual recovery program. Buprenorphine
is going to play a tremendous role in keeping these
individuals in therapy. 
A patient who abuses multiple drugs is likely to
have a difficult time sticking with buprenorphine.
With these patients, you’re likely to get into 12-step,
abstinence-oriented kinds of interventions anyway,
because we don’t have medications for cocaine and
those for alcohol don’t work terribly well. You ask your-
self, ‘Should this be a patient we gradually taper off
the buprenorphine as they learn how to use the 12-
step recovery program?’ I think there is going to be a
role for the gradual buprenorphine taper.
My partners and I are particularly interested in using
buprenorphine to help impaired health care profession-
als. At present, however, I don’t consider buprenorphine
a first-line option for most of these patients. First, 
opioid-dependent physicians generally do well in 
abstinence-based programs, which are more acceptable
in the eyes of society. Second, the article makes an excel-
lent point: We need more research on whether buprenor-
phine impairs cognitive functioning and psychomotor
performance. I suspect it doesn’t, but until I know, I can’t
go before a licensing board and say, ‘This doctor can 
continue to do surgery while taking this medication.’
Payte: If it weren’t for its relatively high cost, I would
see buprenorphine as a trial entry drug for virtually
every new patient coming to our methadone clinics.
But if I were asked to choose among patients, I would
be tempted to give a preferential nod to the younger
patients with shorter abuse histories and less severity,
in consideration of the safety factor. Actually, I would
be prone to refer adolescents for treatment in a physi-
cian’s office rather than expose them to the atmos-
phere of a methadone clinic.
Some established methadone patients also can
gain advantages from switching to buprenorphine,
particularly greater safety. Some want to get away from
the ‘M’ word—the stigma associated with methadone.
Our long-term, stabilized patients now have once-
monthly attendance at many of our clinics, so the
attraction of buprenorphine’s less frequent clinic vis-
its is somewhat attenuated.
Generally, patients will let you know if they are
not doing well on buprenorphine. If their drug
craving persists on what should be an adequate dose—
24 to 32 mg, you may have to switch to the stronger
agonist. But it’s easier to go from buprenorphine to
methadone than the other way around.
Van Zee: I’ve found that I can’t predict very well who’s
going to do well and who isn’t. I’ve seen people do well
who I thought wouldn’t have much of a chance.
And I’ve been disappointed with people who had much
more social and emotional support but didn’t succeed.
I would probably exclude the individual who is obvi-
ously psychiatrically unstable and anyone with impend-
ing legal problems—that is, anyone facing a stay in
prison in the near future. Most often, though not
always, it’s impractical to induce buprenorphine and
maintain a patient on it in jail. 
What I like to see happen is that an individual
is seen by the counselors, starts 12-step meetings, and
then comes to me. I also believe that putting a patient
on buprenorphine should be a decision made by the
entire treatment team. 
Doot: Ideally, you’d like the candidate for buprenor-
phine to have psychosocial stability, be willing to sign
a contract, have adequate resources to follow through,
and have family support. However, we have adjunct
treatments that can overcome many of the problems
that would disqualify patients. If you can supply the
proper psychosocial support—get a patient into a
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halfway house, for example—you have a much bet-
ter chance of success.
It’s important to keep asking, ‘What are we miss-
ing?’ Often there are other treatable conditions that
are standing in the way of recovery from addiction. 
Dosing schedules and diversion
Doot: Some of the early guidelines for buprenorphine
recommended Subutex [buprenorphine alone] for
initiating therapy. In the clinical trial I participated
in, we used Suboxone [buprenorphine combined with
naloxone] for induction, with no problems. I haven’t
seen a need for Subutex in the clinic, and I was pleased
that Dr. Jones clarified that in her paper.
In most situations, I think daily dosing is best.
My patients remember easier to take something once
in the morning than to try to recall if it’s Monday,
Tuesday, or Wednesday. Missing doses could poten-
tially raise the risk for relapse by reducing protection
against craving.
Payte: I agree wholeheartedly. In my brief experience
with buprenorphine, patients have sometimes for-
gotten to take their tablets for a day or two before
finally remembering. Even at that point, they were
fairly comfortable. Buprenorphine just doesn’t give
as strong a reminder as methadone. Also, because
of blood level fluctuations over the dosing inter-
vals, I expect we will obtain the smoothest and best
medication effect by not going to every-other-day
dosing. The rationale for wider dosing intervals would
come into play in clinics whose patients aren’t allowed
take-home doses but who can’t attend every day.
Doot:Some patients actually need the structure of clinic
dispensing. The patients who come to me for office-
based treatment tell me they don’t want to come every
day, but some don’t do well coming in only once a week.
Van Zee:That’s been our experience. In midsummer,
before we tightened up our program, a lot of our
buprenorphine was getting out on the street. Now
we have a minority of patients who don’t get take-
home medication, but instead come to the clinic every
day or every 2 or 3 days. For some, this has been a
real help in getting to clean urines, faithful attendance
at meetings, and so on.
I do feel good about the fact that when buprenor-
phine is diverted onto the street, its downside in terms
of inadvertent overdose is small compared to methadone.
Payte: Methadone diversion is something I’ve been
living with for years. I participated on an Institute of
Medicine panel that tried to determine its impact.
We concluded that the negative effects were difficult
to pinpoint and probably overemphasized as a reason
to deter take-homes. Buprenorphine particularly
reduces the risk even more. 
Doot: I have found that patients on higher buprenor-
phine doses often split their doses. Rather than tak-
ing the full 24 mg in the morning, they will come
back and say, ‘Well, Doc, I took one in the morning
and two at night.’ As long as they take the total daily
dose, those who split it seem to benefit just as well as
those who didn’t.
Van Zee: A small minority of my patients had nausea
if they took the whole dose at once. They did better
splitting the dose.
To save our people money, we only prescribe the
8-mg tablet, not the 2 mg. If someone is on 12 mg a
day, it’s about half as costly to take one-and-a-half 
8-mg tablets as it is to take an 8 and two 2s. Also, the
bigger the quantity purchased at one time, the lower
the price. We have patients buy a whole month’s sup-
ply. If we don’t think a patient should have that much
on hand, we have them buy a month’s supply and store
it at the clinic for dispensing 8 or 10 days at a time.
The learning curve
Van Zee: I’ve learned some things the hard way; in
fact, my program is probably being salvaged by the
nurses and counselors who are making it work in spite
of my mistakes. We have learned two basic lessons:
One, it is a mistake to overstate the value of med-
ication in recovery; and two, you need a tight struc-
ture to have a successful program.
We assumed early on that if the medication took
away the craving and the patients didn’t wake up every
morning sick and thinking about where to get pills,
and their urines were clean, they should do all right.
We underestimated the psychosocial adjustments
needed for recovery, and so set ourselves up for
disappointment when people who seemed to be doing
well would relapse after 3 or 4 months. And we
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were forced to add structure. Now each patient signs
a contract upon entering the program, promising
to attend 12-step meetings 3 times a week and meet
with a counselor once a week. In addition, we do ran-
dom pill counts and urine testing. We have found
that people do better when the requirements are clear. 
Doot: I expect it will continue to be difficult to moti-
vate primary care physicians to ‘hang out their
shingle’ and announce that they intend to take care
of the addicts among their patients. This has been the
disappointment with all the medications developed
so far to treat substance use disorders. Physicians have
tended not to diagnose the problem, perhaps because
they do not have much hope of helping. Buprenorphine
may change that situation. &
     